Pfizer (NYSE:PFE) Stock Price Up 3% – Still a Buy?

Pfizer Inc. (NYSE:PFE) shares rose 3% during trading on Wednesday. The stock traded as high as $29.49 and last traded at $29.2170. Approximately 39,282,235 shares traded hands during trading, a decline of 2% from the average session volume of 40,269,410 shares. The stock had previously closed at $28.37.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Broad IDWeek 2026 pipeline update: Pfizer plans to present more than 50 abstracts, including 12 oral presentations, covering pneumococcal disease, RSV, COVID-19 and Lyme disease. The volume of upcoming clinical data gives investors multiple potential catalysts beyond the company’s COVID-era products. Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
• Positive Sentiment: Next-generation vaccine progress: Pfizer has begun a Phase 3 trial for a next-generation pediatric pneumococcal vaccine, potentially extending the growth runway for its vaccines business. Investors are also watching Phase 3 Lyme vaccine results and additional real-world vaccine data. Pfizer’s Next-Gen Pneumococcal Shot Enters Key Phase 3 Test
• Positive Sentiment: New external innovation deal: Pfizer’s collaboration and licensing agreement with Enodia Therapeutics gives it access to a Sec61 inhibitor platform and adds a new small-molecule discovery program. Pfizer will oversee clinical, regulatory and commercial development, although the financial and development risks remain significant. What Is Pfizer Really Gaining From Its Sec61 Drug Discovery Deal?
• Positive Sentiment: Income support and improving outlook: Pfizer’s roughly 6% dividend yield, recently declared quarterly dividend of $0.43 per share, positive recent clinical updates and improved earnings guidance make the stock attractive to income-focused investors while the pipeline develops. Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline
• Neutral Sentiment: Risks remain: Commentary highlights Pfizer’s elevated dividend payout ratio, while the median analyst price target of about $27 trails the stock’s recent trading level. These factors may limit further upside unless clinical execution and earnings growth improve. Pfizer Pays Out Over 226% of Earnings

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. HSBC upped their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday. Finally, BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.72.

Pfizer Price Performance

The stock has a market capitalization of $166.53 billion, a PE ratio of 38.44, a PEG ratio of 1.92 and a beta of 0.32. The firm’s fifty day moving average price is $27.81 and its two-hundred day moving average price is $26.52. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Institutional Trading of Pfizer

Several hedge funds have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC raised its stake in shares of Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 509 shares during the period. Evolution Wealth Management Inc. boosted its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Keb Asset Management LLC bought a new position in Pfizer during the 2nd quarter valued at about $26,000. Field & Main Bank bought a new position in Pfizer during the 2nd quarter valued at about $27,000. Finally, Global Trust Asset Management LLC raised its position in Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.